Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Moderate Buy" from Analysts : vimarsana.com

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among […]

Related Keywords

Switzerland , Swiss , Nicki Vasquez , Piper Sandler , Sutro Biopharma , Deutsche Bank Aktiengesellschaft , Sutro Biopharma Inc , Securities Exchange Commission , Jpmorgan Chase Co , Nasdaq , Metlife Investment Management , Healthcare Of Ontario Pension Plan Trust Fund , Blackrock Inc , Swiss National Bank , Get Free Report , Bank Aktiengesellschaft , Exchange Commission , National Bank , Ontario Pension Plan Trust Fund , Life Investment Management , Get Free , Sutro Biopharma Daily , Nasdaq Stro , Stro , Medical , Ratings , Consensus ,